Pipeline

Tivic is focused on preventing cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Our lead drug candidate, Entolimod™ to treat Acute Radiation Syndrome (ARS), is in late-stage development under the FDA’s Animal Rule.

Entolimod™ is a TLR5 agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues impacted by radiation and age. Entolasta™ is an immunologically optimized variant of Entolimod for chronic applications.

Entolimod was originally developed as a military countermeasure for acute radiation syndrome. Tivic is working with relevant government agencies to potentially deliver on that indication.

Tivic also sees a significant opportunity for Entolimod™ in oncology. The goal of this approach is to help overcome the substantial challenges associated with treating oncology patient side effects using immunotherapy.

The safety and efficacy of these products have not been established by health authorities. These products are investigational and have not been approved in the US or globally.

MCM = military countermeasure